This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
Novel phenylethynyl-terminated addition-type imide oligomers (degree of polymerization, n=4) derived from 1,2,4,5-benzenetetracarboxylic dianhydride, 2-phenyl-4,4′-diaminodiphenyl ether (p-ODA), which ...
Altman stated, "we expect Japan PMDA clinical review in Q4, FDA meeting request on approvability also in Q4 and a manuscript published in Q1 with CardiAMP Heart Failure II enrollment continuing. For ...
Hosted on MSN
BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025
Peter A. Altman, President and CEO, reported the completion of the CardiAMP Heart Failure trial and noted its primary outcomes were presented as a late-breaking clinical trial at the American College ...
Pharmaceuticals and Medical Devices Agency (PMDA) has succeeded in shortening the review period for medical products to the world's top standard through its 1st and 2nd Mid-term Plan Periods (FY 2004 ...
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) aims to accelerate high-quality drug and medical device reviews to 12 months for at least 70% of new drugs filed for approval with domestic ...
DANBURY, Conn., Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback